Show simple item record

dc.contributor.authorMondal, Samhati
dc.contributor.authorQuintili, Ashley L
dc.contributor.authorKaramchandani, Kunal
dc.contributor.authorBose, Somnath
dc.date.accessioned2020-10-05T19:59:29Z
dc.date.available2020-10-05T19:59:29Z
dc.date.issued2020-09-14
dc.identifier.urihttp://hdl.handle.net/10713/13832
dc.description.abstractCorona virus 2 (SARS-CoV2/ Severe Acute Respiratory Syndrome Corona Virus 2) infection has emerged as a global health crisis. Incidence of thromboembolic disease is reported to be high in SARS-CoV2 disease and is seen in a multitude of organ systems ranging from cutaneous thrombosis to pulmonary embolism, stroke or coronary thrombosis sometimes with catastrophic outcomes. Evidence points towards a key role of thromboembolism, hypercoagulability and over production of proinflammatory cytokines mimicking a "cytokine storm"which leads to multiorgan failure. This brief narrative review highlights the pathophysiology and risk factors of thromboembolic disease and provides a framework for management of anticoagulation based on the current evidence.en_US
dc.description.urihttps://doi.org/10.1186/s40560-020-00483-yen_US
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.relation.ispartofJournal of intensive careen_US
dc.rights© The Author(s) 2020.en_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV2en_US
dc.subjectcoagulationen_US
dc.subjectmanagementen_US
dc.subjectthromboembolismen_US
dc.subjectthrombosisen_US
dc.titleThromboembolic disease in COVID-19 patients: A brief narrative review.en_US
dc.typeArticleen_US
dc.typeOtheren_US
dc.identifier.doi10.1186/s40560-020-00483-y
dc.identifier.pmid32939266
dc.source.volume8
dc.source.beginpage70
dc.source.endpage
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record